Fate Therapeutics Inc (FATE) Stock Price & Analysis
Fate Therapeutics Inc (FATE) rose 2.48% to USD 2.48 as of September 8, 2026 at 04:59 UTC, according to Nexqual real-time market data.
FATE last closed at USD 2.42; the session ranged USD 2.38–2.49 on volume of 611,433 shares. Market capitalization is $297.15M, with a 52-week range of USD 0.93–3.23 (NGM). Source: Nexqual, September 8, 2026 at 04:59 UTC.
Key Statistics (as of September 8, 2026 at 04:59 UTC)
| Price | USD 2.48 |
|---|---|
| Change | ▲ 2.48% (up) |
| Previous Close | USD 2.42 |
| Open | USD 2.38 |
| Day Range | USD 2.38 – 2.49 |
| 52-Week Range | USD 0.93 – 3.23 |
| Volume | 611,433 shares |
| Market Cap | $297.15M |
| Exchange | NGM |
Technical Analysis (FATE)
Nexqual's technical model rates FATE "SELL" based on 1 bullish and 4 bearish signals across 128 daily candles, as of September 8, 2026 at 04:59 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 45.18 (neutral) |
| vs SMA50 | Below (USD 2.63) |
| MACD | -0.04 (negative) |
Analyst Ratings (FATE)
Wall Street analysts rate FATE "Buy" based on 9 analysts, with a mean price target of USD 5.74 (range USD 2.2–8), per Nexqual as of September 8, 2026 at 04:59 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 9 |
| Mean Target | USD 5.74 |
| High Target | USD 8 |
| Low Target | USD 2.2 |
| Buy / Hold / Sell | 5 / 6 / 0 |
Earnings (FATE)
| Next Earnings Date | 2026-11-12 |
|---|---|
| EPS Estimate | USD -0.26 |
| Revenue Estimate | $1.20M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.25 vs est -0.26 ▲ beat |
| 2026-03-31 | USD -0.26 vs est -0.28 ▲ beat |
| 2025-12-31 | USD -0.27 vs est -0.27 ▲ beat |
| 2025-09-30 | USD -0.27 vs est -0.28 ▲ beat |
Source: Nexqual, September 8, 2026 at 04:59 UTC.
Financials & Fundamentals (FATE)
| Total Revenue | $6.49M |
|---|---|
| Revenue Growth (YoY) | +9.20% |
| Gross Margin | +0.00% |
| Operating Margin | -1495.39% |
| Profit Margin | +0.00% |
| ROE | -60.75% |
| Debt / Equity | 49.32 |
| Current Ratio | 4.85 |
| Total Cash | $153.77M |
| Total Debt | $75.67M |
| Free Cash Flow | $-48.66M |
Source: Nexqual, September 8, 2026 at 04:59 UTC.
Financial Health Score (FATE)
Nexqual rates Fate Therapeutics Inc's overall financial health "Weak" across five dimensions, as of September 8, 2026 at 04:59 UTC.
| Growth | Critical — Revenue -51% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $154M cash vs $76M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$49M, burning cash |
| Efficiency | Critical — ROE -61%, ROA -26.2% |
Ownership (FATE)
| Insider Ownership | +1.07% |
|---|---|
| Institutional Ownership | +68.96% |
| Shares Outstanding | 119.82M |
| Float | 105.22M |
| Short % of Float | +8.02% |
Source: Nexqual, September 8, 2026 at 04:59 UTC.
Leadership (FATE)
Fate Therapeutics Inc is led by Bahram Valamehr (age 48), President, CEO & Director, per Nexqual as of September 8, 2026 at 04:59 UTC.
| President, CEO & Director | Bahram Valamehr (age 48) |
|---|---|
| CFO & Treasurer | Kamal Adawi M.S. (age 46) |
| Senior Vice President of Human Resources & Operations | Jessica Francis |
| Senior Vice President of Technical Operations & Quality | Tunde Babalola |
| Senior Director of Investor Relations & Business Development | Ryan Douglas |
Major Backers & Investors (FATE)
Notable institutional backers of Fate Therapeutics Inc include Redmile Group, LLC, Acadian Asset Management. LLC, AQR Capital Management, LLC, according to Nexqual as of September 8, 2026 at 04:59 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Redmile Group, LLC | 10.74% |
| Acadian Asset Management. LLC | 3.63% |
| AQR Capital Management, LLC | 3.2% |
| Two Sigma Investments, LP | 3% |
| Johnson & Johnson | 2.82% |
| Renaissance Technologies | 2.49% |
| Millennium Management | 2.03% |
| Bruce Fund, Inc.-BRUCE FUND | 0.83% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 14.73% |
| BlackRock | 6.82% |
Source: Nexqual, September 8, 2026 at 04:59 UTC.
From Fate Therapeutics Inc's Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally.
- The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity.
- Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors.
- It has a collaboration and option agreement with Ono Pharmaceutical Co.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| TWST | Twist Bioscience Corporation | USD 124.72 | ▼ 4.79% |
| BEAM | Beam Therapeutics Inc. | USD 29.66 | ▲ 1.26% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 8.79 | ▲ 1.97% |
| ALLO | Allogene Therapeutics, Inc. | USD 1.97 | ▼ 0.51% |
| CDNA | CareDx, Inc. | USD 50.88 | ▲ 2.58% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 04:59 UTC. This page is informational and not investment advice.